Besides regulating lipid metabolism, statins have garnered considerable interest because of their antiviral and antineoplastic properties.
The potential benefit of statins using in chronic hepatitis C patients is not well described.
Dr Yi-Xiang Zheng and colleagues performed a meta-analysis to quantitatively assess the efficacy of statins in improving the therapeutic effect and prognosis of patients with chronic hepatitis C.
The team searched electronic databases for relevant studies comparing the course of benefit in CHC patients with statins versus without statins.
|Statin use in chronic HCV was inversely associated with a 55% reduced risk of hepatocellular carcinoma|
|European Journal of Gastroenterology & Hepatology|
Risk estimates were pooled to assess the association of statins use with sustained virological response and the prognosis of chronic hepatitis C patients.
The team identified 23 studies that fulfilled the inclusion criteria.
The researchers showed that 16 homogeneous studies showed that the sustained virological response rate increased by 31% in 12,791 chronic hepatitis C patients with statins as an adjuvant under the general antiviral therapy compared with those without this adjuvant therapy.
Moreover, meta-analysis of 7 studies suggested that statins was beneficial on several specific poor outcomes of chronic hepatitis C patients.
The team found that statin use in chronic hepatitis C patients was inversely associated with a 55% reduced risk of hepatocellular carcinoma, and 53% reduced risk of cirrhosis as well as 44% reduced risk of mortality.
However, significant heterogeneity and publication bias were present in some of our analyses.
Dr Zheng's team commented, "Beneficial effects of statins use were found in the therapy and the prognosis of chronic hepatitis C patients."
"Further prospective studies are still needed to confirm these benefits."